YBSW015
/ Yabao Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 09, 2025
Development and validation of an LC-MS/MS method for pharmacokinetic assessment of a bispecific antibody (YBSW015) targeting SARS-CoV-2.
(PubMed, J Pharm Biomed Anal)
- "YBSW015 concentrations in human serum were determined over the concentration range of 2.00-1000 μg/mL, and the quantification was not interfered by the matrix components and pre-existing antibodies. This precise and sensitive method was successfully employed in a phase I clinical study."
Journal • PK/PD data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 11, 2022
A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, PK and Immunogenicity of YBSW015 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Yabao Pharmaceutical Group
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 2
Of
2
Go to page
1